Novavax (NASDAQ:NVAX) Hits New 1-Year High Following Strong Earnings

Novavax, Inc. (NASDAQ:NVAX) hit a new 52-week high on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as $11.32 and last traded at $11.2660, with a volume of 4677968 shares traded. The stock had previously closed at $9.53.

The biopharmaceutical company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.77. Novavax had a negative return on equity of 836.17% and a net margin of 39.19%.The firm had revenue of $136.40 million for the quarter, compared to analysts’ expectations of $90.26 million. During the same quarter last year, the business posted ($0.51) EPS. Novavax’s revenue was up 66.6% on a year-over-year basis.

Key Headlines Impacting Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Q4 results beat: Novavax reported a surprise GAAP profit (EPS $0.11) and ~67% year‑over‑year revenue growth, driven by licensing/milestone revenues — the core reason the stock jumped on the news. Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates
• Positive Sentiment: Strong operational highlights and balance sheet: Full‑year 2025 revenue of ~$1.1B, $225M Sanofi milestones earned, and year‑end cash of ~$751M reduce short‑term financing risk and support pipeline investments. Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
• Positive Sentiment: Analyst upgrade: HC Wainwright raised its price target to $16 and kept a Buy rating, signaling bullish conviction from at least one sell‑side shop. Benzinga
• Neutral Sentiment: Investor access: Management will present at upcoming investor conferences (TD Cowen fireside chat, others) — useful for transparency but not a near‑term catalyst by itself. Novavax to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Market activity: Unusual options flow showed heavy call buying around the earnings move, indicating elevated short‑term speculative interest. (This reflects trader positioning, not fundamental change.)
• Neutral Sentiment: Earnings call transcript posted for deeper detail on results and guidance assumptions. Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript
• Negative Sentiment: 2026 revenue guidance disappointed relative to consensus: Management guided revenue of $230M–$270M for 2026, well below street estimates (~$402M), creating concern about demand trends and prompting profit‑taking. Novavax Q4 Press Release / Guidance
• Negative Sentiment: Analyst caution remains: Some analysts argue the bull case needs more proof despite the beat — concerns on sustainability of licensing revenue, product demand and execution could cap multiple expansion. Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof

Analyst Upgrades and Downgrades

A number of research firms recently commented on NVAX. HC Wainwright raised their price objective on shares of Novavax from $11.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday. TD Cowen decreased their target price on Novavax from $8.00 to $7.00 and set a “hold” rating for the company in a research report on Tuesday, November 4th. JPMorgan Chase & Co. dropped their price target on Novavax from $7.00 to $6.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 18th. Weiss Ratings reissued a “sell (d+)” rating on shares of Novavax in a research note on Monday, December 29th. Finally, B. Riley Financial restated a “buy” rating and set a $16.00 price objective (down from $18.00) on shares of Novavax in a research report on Monday, November 10th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat, Novavax has an average rating of “Hold” and an average price target of $11.88.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Invesco Ltd. increased its holdings in Novavax by 12.9% in the fourth quarter. Invesco Ltd. now owns 259,380 shares of the biopharmaceutical company’s stock worth $1,743,000 after buying an additional 29,704 shares during the last quarter. VARCOV Co. bought a new stake in Novavax in the fourth quarter worth approximately $263,000. Virtus Investment Advisers LLC increased its stake in shares of Novavax by 67.4% during the 4th quarter. Virtus Investment Advisers LLC now owns 104,019 shares of the biopharmaceutical company’s stock worth $699,000 after purchasing an additional 41,866 shares during the last quarter. Oxford Asset Management LLP acquired a new position in shares of Novavax during the 4th quarter worth $145,000. Finally, Man Group plc bought a new position in shares of Novavax during the 4th quarter valued at $290,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Novavax Stock Performance

The company has a debt-to-equity ratio of 5.93, a quick ratio of 2.24 and a current ratio of 2.27. The firm’s 50 day moving average is $8.34 and its 200-day moving average is $8.03. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of 4.21 and a beta of 2.58.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.